Advertisement

BioDrugs

pp 1–10 | Cite as

In Search of Predictors of Switching Between Erythropoiesis-Stimulating Agents in Clinical Practice: A Multi-Regional Cohort Study

  • Ylenia IngrasciottaEmail author
  • Valeria Belleudi
  • Francesco Trotta
  • Antonio Addis
  • Andrea Fontana
  • Alessandro Chinellato
  • Valentina Ientile
  • Daniele Ugo Tari
  • Giuseppe Roberto
  • Maurizio Pastorello
  • Salvatore Scondotto
  • Pasquale Cananzi
  • Giuseppe Traversa
  • Marina Davoli
  • Mariangela Rossi
  • Gianluca Trifirò
  • On behalf of the Italian Biosimilars Network (I-BioNetwork)
Original Research Article

Abstract

Background and objectives

Switching between different erythropoiesis-stimulating agents (ESAs) during the first year of therapy is frequent (15–20%), much more so toward reference products than biosimilars. The objectives of this study were to investigate the frequency and identify the potential predictors of switching between biosimilar and originator ESAs during the first year of treatment in patients with chronic kidney disease (CKD), or chemotherapy-related anemia from six large Italian geographic areas in the years 2009–2015.

Methods

A retrospective cohort study was conducted using six Italian regional claims databases (≥ 13 million inhabitants) during 2009–2015. Among incident epoetin users, the frequency of single, multiple, and backward switch during the first year of treatment was evaluated. Using frailty Cox models, potential predictors of first switch were identified. All analyses were stratified by the main indications for use.

Results

Among 102,240 incident epoetin users, 15,853 (15.5%) switched to another epoetin during the first year of therapy; only 18% of these switched to biosimilars. Single switch was more common (62.2% of the switchers) than multiple (23.5%) or backward switch (14.3%). In cancer, the cumulative number of transfusions and iron preparations dispensed, as well as hyperparathyroidism, were predictors of switching. In CKD, the cumulative number of transfusions, number of vitamin A/D preparations dispensed, and CKD severity increased the probability of switching.

Conclusions

Switching between ESAs was frequent in both CKD and cancer patients. The number of cumulative transfusions and severity of disease seemed to affect the switch.

Notes

Acknowledgements

Ylenia Ingrasciotta, Valentina Ientile, Alessandro Chinellato, Michele Tari, Giuseppe Roberto, Andrea Fontana, Maurizio Pastorello, Salvatore Scondotto, Pasquale Cananzi, Giuseppe Traversa, Marina Davoli, Francesco Trotta, Valeria Belleudi, Antonio Addis, Domenico Santoro, and Gianluca Trifirò are members of the I-BioNetwork. The authors thank Achille P. Caputi, Jenny Bolcato, Rosa Gini, Roberta Pirolo, Pastorello, Ilaria Uomo, Sebastiano W. Pollina Addario, Roberto Da Cas, Mariangela Rossi, and Armando Genazzani, who are also members of the I-BioNetwork.

Author contributions

GTri, YI, VB, FT, and AA generated the study idea. YI wrote the final manuscript. VI, AF, and YI performed the data analysis. MR, VB, AC, GR, MP, SS, and GTra extracted the data and authorized their utilization. DS, GTri, and YI assisted in interpreting the results from a clinical perspective. All authors assisted interpretation of the results and manuscript revision and read and approved the final manuscript.

Compliance with Ethical Standards

Funding

This study was conducted in the context of the finalized research project “Assessment of Short and Long Term Risk–Benefit Profile of Biologics through Healthcare Database Network in Italy” (RF-2010-2320172), which was funded by the Italian Health Ministry. The financial assistance was used to access and analyze data from different partners.

Conflict of interest

Gianluca Trifirò declares his participation in advisory boards on biosimilars, organized by Sandoz and Hospira; furthermore, he coordinates a pharmacoepidemiology research team at the University of Messina, which receives research grants for projects that are not related to the topic of the paper. Ylenia Ingrasciotta, Valeria Belleudi, Francesco Trotta, Antonio Addis, Andrea Fontana, Alessandro Chinellato, Valentina Ientile, Daniele Ugo Tari, Giuseppe Roberto, Maurizio Pastorello, Salvatore Scondotto, Pasquale Cananzi, Giuseppe Traversa, Marina Davoli, and Mariangela Rossi declare that they have no conflicts of interest that might be relevant to the contents of this study.

Ethical approval

This study was conducted in the context of the “Assessment of Short and Long Term Risk–Benefit Profile of Biologics through Healthcare Database Network in Italy” project, funded by the Italian Ministry of Health. The study protocol was notified to the Ethical Committee of the Academic Hospital of Messina [31], according to the current national law. The manuscript does not contain clinical studies or patient data. For this type of study formal consent is not required.

References

  1. 1.
    Italian Association of Medical Oncology. Linee guida gestione della tossicità ematopoietica in oncologia. 2017. http://media.aiom.it/userfiles/files/doc/LG/2017_LGAIOM_Toss_ematopoietica.pdf. Accessed 2 Oct 2019.
  2. 2.
    Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist. 2008;13(Suppl 3):33–6.CrossRefGoogle Scholar
  3. 3.
    Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Somerfield MR, Temin S. American society of clinical oncology/american society of hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Oncol Pract. 2010;6(6):317–20.CrossRefGoogle Scholar
  4. 4.
  5. 5.
    Quintiles. The impact of biosimilar competition in Europe. Quintiles IMS. 2017. http://www.medicinesforeurope.com/wp-content/uploads/2017/05/IMS-Biosimilar-2017_V9.pdf. Accessed 2 Oct 2019.
  6. 6.
    Dylst P, Vulto A, Simoens S. Barriers to the uptake of biosimilars and possible solutions: a Belgian case study. Pharmacoeconomics. 2014;32(7):681–91.CrossRefGoogle Scholar
  7. 7.
    Rompas S, Goss T, Amanuel S, Coutinho V, Lai Z, Antonini P, et al. Demonstrating value for biosimilars: a conceptual framework. Am Health Drug Benefits. 2015;8(3):129–39.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Trifirò G, Marcianò I, Ingrasciotta Y. Interchangeability of biosimilar and biological reference product: updated regulatory positions and pre- and post-marketing evidence. Expert Opin Biol Ther. 2018;18(3):309–15.CrossRefGoogle Scholar
  9. 9.
    European Medicines Agency (EMA). Biosimilars in the EU, Information guide for healthcare professionals. 2017. https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. Accessed 2 Oct 2019.
  10. 10.
    Agenzia Italiana del Farmaco (AIFA). Secondo position paper AIFA sui Farmaci Biosimilari. 2018.Google Scholar
  11. 11.
    Agenzia Italiana del Farmaco (AIFA). L’uso dei farmaci in Italia. Rapporto Nazionale anno 2017. 2018. http://www.aifa.gov.it/sites/default/files/Rapporto_OsMed_2017_AIFA.pdf. Accessed 2 Oct 2019.
  12. 12.
    Ingrasciotta Y, Giorgianni F, Bolcato J, Chinellato A, Pirolo R, Tari DU, et al. How much are biosimilars used in clinical practice? A retrospective Italian population-based study of erythropoiesis-stimulating agents in the years 2009–2013. BioDrugs. 2015;29(4):275–84.CrossRefGoogle Scholar
  13. 13.
    Food and Drug Administration. Considerations in demonstrating interchangeability with a reference product guidance for industry. 2017. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM537135.pdf. Accessed 2 Oct 2019.
  14. 14.
    European Medicines Agency (EMA). Committee for Medicinal Products for Human Use (CHMP): guideline on similar biological medicinal products. 2014. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-rev1_en.pdf. Accessed 2 Oct 2019.
  15. 15.
    Loiacono C, Sgroi C, Coppolino S, Cannata A, Ferrara R, Arcoraci V. How much are biosimilars used in Southern Italy? A retrospective analysis of epoetin utilization in the local health unit of Messina in the years 2010–2011. BioDrugs. 2012;26(2):113–20.CrossRefGoogle Scholar
  16. 16.
    D’Amore C, Da Cas R, Rossi M, Traversa G. Switching between epoetins: a practice in support of biosimilar use. BioDrugs. 2016;30(1):27–32.CrossRefGoogle Scholar
  17. 17.
    Locatelli F, Andrulli S, Memoli B, Maffei C, Del Vecchio L, Aterini S, et al. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant. 2006;21(4):991–8.CrossRefGoogle Scholar
  18. 18.
    KDOQI, National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47(5 Suppl 3):S11–145.Google Scholar
  19. 19.
    Fine JP, Glidden DV, Lee KE. A simple estimator for a shared frailty regression model. J R Stat Soc Ser B Stat Methodol. 2003;65(1):317–29.CrossRefGoogle Scholar
  20. 20.
    Agenzia Italiana del Farmaco (AIFA). Position paper sui farmaci biosimilari (28/05/2013). http://www.agenziafarmaco.gov.it/sites/default/files/AIFA_POSITION_PAPER_FARMACI_BIOSIMILARI.pdf. Accessed 2 Oct 2019.
  21. 21.
    Lonnemann G, Wrenger E. Biosimilar epoetin zeta in nephrology—a single-dialysis center experience. Clin Nephrol. 2011;75(1):59–62.PubMedGoogle Scholar
  22. 22.
    Belleudi V, Trotta F, Addis A, et al. Italian Biosimilar Network (ItaBioNet). Effectiveness and safety of switching originator and biosimilar epoetins in patients with chronic kidney disease in a large-scale Italian cohort study. Drug Saf. 2019.  https://doi.org/10.1007/s40264-019-00845-y.CrossRefPubMedGoogle Scholar
  23. 23.
    Nagata S, Ikegaya N, Ogino S, Uchida S, Itaya M, Momita A, et al. The resection of thyroid cancer was associated with the resolution of hyporesponsiveness to an erythropoiesis-stimulating agent in a hemodialysis patient with aceruloplasminemia. Intern Med. 2017;56(7):805–10.CrossRefGoogle Scholar
  24. 24.
    Solomon SD, Uno H, Lewis EF, Eckardt K-U, Lin J, Burdmann EA, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010;363(12):1146–55.CrossRefGoogle Scholar
  25. 25.
    Gilbertson DT, Ebben JP, Foley RN, Weinhandl ED, Bradbury BD, Collins AJ. Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol. 2008;3(1):133–8.CrossRefGoogle Scholar
  26. 26.
    Grützmacher P, Ehmer B, Limbach J, Messinger D, Kulbe KD, Scigalla P. Treatment with recombinant human erythropoietin in patients with aluminum overload and hyperparathyroidism. Blood Purif. 1990;8(5):279–84.CrossRefGoogle Scholar
  27. 27.
    Ingrasciotta Y, Giorgianni F, Marcianò I, Bolcato J, Pirolo R, Chinellato A, et al. Comparative effectiveness of biosimilar, reference product and other erythropoiesis-stimulating agents (ESAs) still covered by patent in chronic kidney disease and cancer patients: an Italian population-based study. PLoS One. 2016;11(5):1–16.CrossRefGoogle Scholar
  28. 28.
    Marcianò I, Ingrasciotta Y, Giorgianni F, Bolcato J, Chinellato A, Pirolo R, et al. How did the introduction of biosimilar filgrastim influence the prescribing pattern of granulocyte colony-stimulating factors? Results from a multicentre, population-based study, from five Italian centres in the years 2009–2014. BioDrugs. 2016;30(4):295–306.CrossRefGoogle Scholar
  29. 29.
    Marcianò I, Ingrasciotta Y, Giorgianni F, et al. Pattern of use of biosimilar and originator somatropin in italy: a population-based multiple databases study during the years 2009–2014. Front Endocrinol (Lausanne). 2018;9:95.CrossRefGoogle Scholar
  30. 30.
    Bohlius J, Bohlke K, Castelli R, Djulbegovic B, Lustberg MB, Martino M, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. J Clin Oncol. 2019;37(15):1336–51.  https://doi.org/10.1200/JCO.18.02142.CrossRefPubMedGoogle Scholar
  31. 31.
    Ministero della Salute, Agenzia Italiana del Farmaco (AIFA). Circolare AIFA del 3 agosto 2007. Linee guida per la classificazione e conduzione degli studi osservazionali sui farmaci. http://xoomer.virgilio.it/pgiuff/osservazionali.pdf. Accessed 14 Dec 2015.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Ylenia Ingrasciotta
    • 1
    Email author
  • Valeria Belleudi
    • 2
  • Francesco Trotta
    • 3
  • Antonio Addis
    • 2
  • Andrea Fontana
    • 4
  • Alessandro Chinellato
    • 5
  • Valentina Ientile
    • 1
  • Daniele Ugo Tari
    • 6
  • Giuseppe Roberto
    • 7
  • Maurizio Pastorello
    • 8
  • Salvatore Scondotto
    • 9
  • Pasquale Cananzi
    • 10
  • Giuseppe Traversa
    • 11
  • Marina Davoli
    • 2
  • Mariangela Rossi
    • 12
  • Gianluca Trifirò
    • 1
    • 13
  • On behalf of the Italian Biosimilars Network (I-BioNetwork)
  1. 1.Department of Biomedical and Dental Sciences and Morphofunctional ImagingUniversity of MessinaMessinaItaly
  2. 2.Department of EpidemiologyLazio Regional Health ServiceRomeItaly
  3. 3.Italian Medicines AgencyRomeItaly
  4. 4.Unit of BiostatisticsCasa Sollievo della SofferenzaSan Giovanni RotondoItaly
  5. 5.Pharmaceutical ServiceLocal Health Authority (ULSS9)TrevisoItaly
  6. 6.Caserta-1 Local Health ServiceCasertaItaly
  7. 7.Epidemiology UnitRegional Agency for Healthcare Services of TuscanyFlorenceItaly
  8. 8.Department of PharmacyPalermo Local Health UnitPalermoItaly
  9. 9.Department of Epidemiologic ObservatoryHealth Department of SicilyPalermoItaly
  10. 10.Sicilian Regional Centre of Pharmacovigilance, Servizio 7-FarmaceuticaHealth Department of SicilyPalermoItaly
  11. 11.Pharmacoepidemiology Unit, National Centre for EpidemiologyItalian National Institute of HealthRomeItaly
  12. 12.Health-Unit for Pharmaceutical GovernancePerugiaItaly
  13. 13.Unit of Clinical PharmacologyA.O.U. Policlinico “G. Martino”MessinaItaly

Personalised recommendations